Trials / Completed
CompletedNCT05890001
A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- Braintree Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BLI5100 | Patients will take BLI5100 once daily, orally, for up to 29 weeks. |
Timeline
- Start date
- 2023-04-05
- Primary completion
- 2024-10-08
- Completion
- 2024-10-08
- First posted
- 2023-06-05
- Last updated
- 2025-09-26
Locations
60 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05890001. Inclusion in this directory is not an endorsement.